Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Sildenafil and inhaled nitric oxide (iNO) | Persistent Pulmonary Hypertension (PPHN) | Phase 3 | Sildenafil oral iNO inhalation | Cardiology | |
| Pfizer Inc. | Tucatinib + ado-trastuzumab emtansine (T-DM1, Kadcyla), - (HER2CLIMB-02) | HER2+ Metastatic Breast Cancer (MBC) | Phase 3 | Data Released | Oral and intravenous | Oncology |
| Pfizer Inc. | Sildenafil and inhaled nitric oxide (iNO) | Persistent Pulmonary Hypertension (PPHN) | Phase 3 | Sildenafil oral iNO inhalation | Cardiology | |
| Pfizer Inc. | LYRICA (pregabalin) | Primary generalized tonic-clonic (PGTC) seizures - epilepsy | Phase 3 | Oral | Neurology | |
| Pfizer Inc. | PF-06425090 | C. difficile Infection | Phase 3 | Intramuscular | Antibiotic | |
| Pfizer Inc. | IBRANCE (palbociclib) - (PALLAS) | Early stage breast cancer | Phase 3 | Data Released | Oral | Oncology |
| Pfizer Inc. | IBRANCE (palbociclib) - PENELOPE-B | Early stage breast cancer | Phase 3 | Oral | Oncology | |
| Pfizer Inc. | Troriluzole | Spinocerebellar Ataxia (SCA) | Phase 3 | Withdrawn | Oral | Neurology |
